Oncotarget is a medical journal that covers oncology. It was started in 2010. The journal is open-access which means that anyone can access the issues that they release. It is also peer-reviewed. This means that an article has to be reviewed by several members of the scientific community before it is published. The journal prints papers and issues upon request.
According to Research Gate, Andrei Gudkov and Mikhail Blagosklonny are the senior editors of Oncotarget. Gudkov is a professor of cell stress biology. He is also the vice president of basic research at the Roswell Park Cancer Institute. Blagosklonny also works at the Institute and is a professor of oncology. His research involves cancer treatment, aging, and anti-aging strategies.
The editorial board of the journal is made up of distinguished researchers and scholars who ensure that the journal maintains its high standards. They also cover other areas which are related to oncology including gerotarget, pathology, and endocrinology even though they started by publishing papers in the field of oncology only.
The journal now provides free Altmetric article reports so that authors can see the performance of articles published on Oncotarget. This is in line with their goal of providing the best experience to authors whose papers are published in the journal.
The journal is indexed and abstracted by Scopus, PubMed, and the Science Citation Index Expanded. Oncotarget has been a top journal in Scopus’ ranking and has been in its highest rank since 2011. The journal had an impact factor of 5.4 last year and an average of 5.0 since it was started. According to Research Gate, Oncotarget currently ranks as the top journal among all journals on Oncology in the world. This is because of the experience of the editors and their commitment to the mission of the magazine.
Oncotarget’s mission has been to ensure that there is the rapid publication of outstanding research. This is why the issues are released online on a weekly basis. The journal maximizes the impact of research since it can be viewed by people from anywhere in the world. Oncotarget has allowed the collaboration of researchers from different fields by expanding the fields that they cover.